Infant Mortality Reduction by the Mass Administration of Azithromycin

Running, not enrolling · Phase 4 · Has a placebo group

Conditions studied: Child Mortality

In brief

This trial will investigate the supplementation of azithromycin distribution to the "Child Health Days" platform in Burkina Faso for child mortality reduction. This distribution will pair door-to-door administration of vitamin A and azithromycin or placebo with acute malnutrition screening among children 1-11 months old.

Key facts

Study ID

NCT04716712

Run by

University of California, San Francisco

People needed

694400

Starts

2021-10-04

Expected to finish

2026-01-30

Last updated by the study team

2025-03-13

Who can join

Age: 0 and older, up to 1. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Community eligibility criteria:
• Located in one of the three selected regions: SudOuest, Centre-Ouest, Hauts-Bassins
• Verbal consent of the community leader is obtained
• Inclusion criteria for children:
• Aged 1 to 11 months
• Living in one of the communities participating in the study

You may not qualify if…

• Community exclusion criteria:
• Inaccessible or unsafe for the study team
• Exclusion criteria for children:
• Known allergy to macrolides

Where it is running

• University of California, San Francisco — San Francisco, California, United States
• Centre de Recherche en Sante de Nouna — Nouna, Burkina Faso
• Helen Keller International — Ouagadougou, Burkina Faso

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.